Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Head & Neck 1Endocrine 1CNS 1

Conditions

Neuroendocrine Tumors 9Thyroid Neoplasms 3Thyroid Cancer, Papillary 3Carcinoma, Medullary 3Carcinoid Tumor 3Adrenocortical Carcinoma 3Adenocarcinoma, Follicular 3Pheochromocytoma 2Paraganglioma 2Carcinoma, Renal Cell 2Carcinoma, Neuroendocrine 2Adenoma, Islet Cell 2Wilms Tumor 1Thyroid cancer, medullary 1Thyroid cancer, follicular 1Thyroid Diseases 1Thyroid Carcinoma, Anaplastic 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Rhabdomyosarcoma 1Paraganglioma, Extra-Adrenal 1Osteosarcoma 1Non functioning pancreatic endocrine tumor 1Neoplasm Metastasis 1Metastatic Digestive System Neuroendocrine Tumor G1 1High Grade Neuroendocrine Neoplasms 1Hepatoblastoma 1

Interventions

Paclitaxel 10trametinib 9dabrafenib 9pembrolizumab 5lenvatinib 5fosbretabulin 4Sorafenib 4Radiotherapy, Intensity-Modulated 4Doxorubicin 4Radiotherapy 3Cisplatin 3pazopanib 2efatutazone 2combretastatin 2cobimetinib 2cemiplimab 2atezolizumab 2aldesleukin 2Vemurafenib 2Trastuzumab 2Taxes 2Nivolumab 2Gefitinib 2Filgrastim 2Everolimus 2Docetaxel 2Carboplatin 2Bevacizumab 2zimberelimab 1vandetanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid Carcinoma, Anaplastic × cabozantinib × Endocrine × Clear all
NCT04400474 2025-06-19

CABATEN

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Completed
93 enrolled 17 charts
CNSEndocrineHead & NeckNET

Adenocarcinoma, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡